X4 Pharmaceuticals Inc.
784 Memorial Drive
X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc. spun out from Sanofi to develop compounds that target the CXCR4/CXCL12 receptor pathway to restore immune cell surveillance against cancer.
More from Archive
More from Scrip
• By
The osteogenesis imperfecta drug stumbled in a second interim analysis.
Recent moves in the industry include C-suite changes at Essential Pharma, plus Kyverna Therapeutics gets new chief financial officer from Alector.
• By
The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.